Bexarotene in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 31, 1998

Study Completion Date

March 31, 2003

Conditions
Breast Cancer
Interventions
DRUG

bexarotene

Trial Locations (30)

10021

Memorial Sloan-Kettering Cancer Center, New York

19104

University of Pennsylvania Cancer Center, Philadelphia

20007

Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C.

22908

Cancer Center, University of Virginia HSC, Charlottesville

32207

Baptist Regional Cancer Institute - Jacksonville, Jacksonville

32224

Mayo Clinic Jacksonville, Jacksonville

33136

Sylvester Cancer Center, University of Miami, Miami

35294

University of Alabama Comprehensive Cancer Center, Birmingham

37203

Sarah Cannon-Minnie Pearl Cancer Center, Nashville

43210

Arthur G. James Cancer Hospital - Ohio State University, Columbus

43235

Hematology Oncology Consultants Inc, Columbus

48824

Michigan State University, East Lansing

55455

University of Minnesota, Minneapolis

60611

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

72205

University of Arkansas for Medical Sciences, Little Rock

77030

University of Texas - MD Anderson Cancer Center, Houston

85724

Arizona Cancer Center, Tucson

91010

Beckman Research Institute, City of Hope, Los Angeles

92120

Kaiser Permanente-Southern California Permanente Medical Group, San Diego

96813

Cancer Research Center of Hawaii, Honolulu

90033-0800

USC/Norris Comprehensive Cancer Center, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

06520-8028

Yale Comprehensive Cancer Center, New Haven

70112-2822

Louisiana State University School of Medicine, New Orleans

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

68198-3330

University of Nebraska Medical Center, Omaha

97201-3098

Oregon Cancer Center at Oregon Health Sciences University, Portland

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY

NCT00003752 - Bexarotene in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter